Sign In
Buy PRTK
$2.23
+0 (+0%)
At Close: Dec 19, 2023
Paratek (PRTK) Moves 14.5% Higher: Will This Strength Last?
03:11pm, Monday, 12'th Apr 2021
Paratek (PRTK) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Thursday, 01'st Apr 2021
BOSTON, April 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:01pm, Monday, 01'st Mar 2021
BOSTON, March 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-sav
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2020 Results - Earnings Call Transcript
09:38pm, Wednesday, 24'th Feb 2021
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q4 2020 Results - Earnings Call Transcript
Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Misses Revenue Estimates
06:56pm, Wednesday, 24'th Feb 2021
Paratek (PRTK) delivered earnings and revenue surprises of -712.50% and -59.53%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
-- NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020 -- NUZYRA Expansion into the Primary Care Setting in 2021
Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
04:01pm, Wednesday, 17'th Feb 2021
BOSTON, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Monday, 01'st Feb 2021
BOSTON, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOs
03:16pm, Sunday, 10'th Jan 2021
Gracell Biotech completed a $209 million NASDAQ IPO for its next-gen CAR-T treatments. Zai Lab acquired greater China rights to an argenx SE novel treatment for autoimmune indications in a deal worth
Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc. Proceeds Used to Prepay Outstanding Loan with Hercules Capital, Inc.
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
04:05pm, Tuesday, 01'st Dec 2020
BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
08:27am, Tuesday, 01'st Dec 2020
Nuzyra launch trajectory is top of class compared with other antibiotics. BARDA deal signed late 2019 is worth $285M.
Paratek Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
04:01pm, Thursday, 12'th Nov 2020
BOSTON, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2020 Results - Earnings Call Transcript
02:21pm, Friday, 06'th Nov 2020
Paratek Pharmaceuticals, Inc. (PRTK) CEO Evan Loh on Q3 2020 Results - Earnings Call Transcript
Paratek Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 5, 2020
08:00am, Tuesday, 27'th Oct 2020
BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-savi
